Abstract
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is involved in the pathogenesis and progression of several cancers. However, the potential effect of MALAT1 in primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) has not been elucidated. This study aimed to explore the prognostic value of MALAT1 in patients with PGI-DLBCL. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to determine the expression of MALAT1 in 90 patients with PGI-DLBCL. MALAT1 was remarkably upregulated in PGI-DLBCL tissues compared to paired adjacent non-tumor tissues (P < 0.001), and the area under the receiver operating characteristic (ROC) curve (AUC) was 0.838. MALAT1 expression was further increased in the non-germinal center B-cell-like (non-GCB), advanced stage (stages IIE-IV) and International Prognostic Index (IPI) score (3-5) groups (P = 0.01, P < 0.001 and P < 0.001, respectively). Furthermore, Kaplan-Meier analysis showed that elevated MALAT1 expression correlated with inferior overall survival (OS) and progression-free survival in PGI-DLBCL patients (P < 0.001 and P < 0.001, respectively), and our multivariate analysis results suggested that upregulation of MALAT1 and high IPI score (3-5) were two unfavorable prognostic factors for PGI-DLBCL. In conclusion, our results demonstrate that MALAT1 may serve as a novel prognostic biomarker and an ideal therapeutic target for patients with PGI-DLBCL.
Highlights
The most common extranodal site of non-Hodgkin's lymphoma (NHL) is the gastrointestinal (GI) tract, constituting about 5%–20% of all NHLs and 30%–40% of all extranodal lymphoma [1]
Researchers have found a large number of long non-coding RNAs (lncRNAs) and proved that they were related to the occurrence and development of human diseases, especially in cancers, which could promote cancer cell proliferation, invasion and metastasis [36]
Emerging reports have shown that lncRNAs can be used as biomarkers to predict the diagnosis and prognosis of human tumors as well as therapeutic targets for tumor treatment
Summary
The most common extranodal site of non-Hodgkin's lymphoma (NHL) is the gastrointestinal (GI) tract, constituting about 5%–20% of all NHLs and 30%–40% of all extranodal lymphoma [1]. Primary GI (PGI) lymphoma is a relatively rare disease, accounting for only 1‐4% of all GI malignant tumors [2]. Diffuse large B‐cell lymphoma (DLBCL) is the most common histopathological subtype of PGI lymphoma, following mucosa-associated lymphoid tissue (MALT) lymphoma and follicular lymphoma, respectively [5,6]. The etiology of primary gastrointestinal diffuse large B‐cell lymphoma (PGI-DLBCL) remains largely elusive. Recent studies have shown that long non-coding RNAs (lncRNAs) serve as new biomarkes for diagnosis and therapy of diverse cancers, and the aberrant expression are widely associated with pathogenesis, metastasis, and tumor stage [7,8,9]. The molecular mechanism and clinical significance of lncRNAs on PGI-DLBCL patients has not been reported
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
